Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 3 - 17
Published: Nov. 29, 2024
Language: Английский
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 14
Published: Jan. 8, 2024
Immunoglobulin G (IgG) antibodies are a critical component of the adaptive immune system, binding to and neutralizing pathogens other foreign substances. Recent advances in molecular antibody biology structural protein engineering enabled modification IgG enhance their therapeutic potential. This review summarizes recent progress both natural engineered modifications antibodies, including allotypic variation, glycosylation, Fc engineering, gamma receptor optimization. We discuss functional consequences these highlight potential for therapeutical applications.
Language: Английский
Citations
36
ImmunoHorizons, Journal Year: 2023, Volume and Issue: 7(12), P. 886 - 897
Published: Dec. 1, 2023
Abstract mAbs are highly indispensable tools for diagnostic, prophylactic, and therapeutic applications. The first technique, hybridoma technology, was based on fusion of B lymphocytes with myeloma cells, which resulted in generation single against a specific Ag. Along several novel alternative methods have been developed to improve mAb generation, ranging from electrofusion the discovery completely technologies such as cell immortalization; phage, yeast, bacterial, ribosome, mammalian display systems; DNA/RNA encoded Abs; technology; transgenic animals; artificial intelligence/machine learning. This commentary outlines evolution, methodology, advantages, limitations various production techniques. Furthermore, advent next-generation Ab single-chain variable fragments, nanobodies, bispecific Abs, Fc-engineered biosimilars, mimetics, Ab-drug conjugates, healthcare pharmaceutical sectors become resourceful develop treatments diseases cancer autoimmune infectious diseases.
Language: Английский
Citations
30
Biomedicines, Journal Year: 2024, Volume and Issue: 12(9), P. 2158 - 2158
Published: Sept. 23, 2024
Cancer immunotherapy has emerged as a transformative approach in oncology, utilizing the body’s immune system to specifically target and destroy malignant cells. This review explores scope impact of various immunotherapeutic strategies, including monoclonal antibodies, chimeric antigen receptor (CAR)-T cell therapy, checkpoint inhibitors, cytokine therapeutic vaccines. Monoclonal such Rituximab Trastuzumab, have revolutionized treatment paradigms for lymphoma breast cancer by offering targeted interventions that reduce off-target effects. CAR-T therapy presents potentially curative option refractory hematologic malignancies, although challenges remain effectively treating solid tumors. Checkpoint inhibitors redefined management cancers like melanoma lung cancer; however, managing immune-related adverse events ensuring durable responses are critical areas focus. Cytokine continues play vital role modulating response, with advancements engineering improving specificity reducing systemic toxicity. Therapeutic vaccines, particularly mRNA-based represent frontier personalized treatment, aiming generate robust, long-lasting against tumor-specific antigens. Despite these advancements, field faces significant challenges, resistance, tumor heterogeneity, immunosuppressive microenvironment. Future research should address obstacles through emerging technologies, next-generation Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-based gene editing, AI-driven drug discovery. By integrating novel approaches, holds promise more durable, less toxic, highly options, ultimately patient outcomes survival rates.
Language: Английский
Citations
10
Plant Biotechnology Reports, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 21, 2025
Language: Английский
Citations
1
Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14
Published: April 30, 2024
Over 160 therapeutic and in vivo diagnostic monoclonal antibodies have been approved by the US FDA since first antibody, muromonab, was 1986. Approximately 42% of these approvals were for treatment or diagnosis oncology indications, although some products are no longer marketed. This review will look at history antibody development approvals, discuss current antibody-based modalities, regulatory considerations engineering approaches, critical quality attributes different immunogenicity mAbs across products, future directions products.
Language: Английский
Citations
8
Molecular Biotechnology, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 2, 2024
Language: Английский
Citations
5
mAbs, Journal Year: 2024, Volume and Issue: 16(1)
Published: Sept. 15, 2024
Elimination of the binding immunoglobulin Fc to gamma receptors is highly desirable for avoidance unwanted inflammatory responses therapeutic antibodies and fusion proteins. Many different approaches have been used in clinic, but they not systematically compared. We now produced a matched set anti-CD20 with subclasses variants compared their activity C1q, Fc-gamma cell-based assays. Most still significant levels one or more these assays many them impaired temperature stability corresponding wild-type antibody.
Language: Английский
Citations
5
mAbs, Journal Year: 2024, Volume and Issue: 16(1)
Published: Sept. 22, 2024
A critical attribute of therapeutic antibodies is their ability to engage with humoral or cellular effector mechanisms, and this depends on the Fc region bind complement (C1q) receptors. Investigators have sought optimize these effects by engineering a greater lesser extent individual Different approaches been used in clinic, but they not systematically compared. We now produced matched set anti-CD20 representing range variants compared activity cell-based assays for complement-dependent cytotoxicity, antibody-dependent cell-mediated phagocytosis using also thermal stability differential scanning fluorimetry (DSF). The results reveal spectrum activities which may be appropriate different applications.
Language: Английский
Citations
5
Molecular Biomedicine, Journal Year: 2024, Volume and Issue: 5(1)
Published: Oct. 11, 2024
Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable communicable diseases. Over the past few years, market for mAbs has grown exponentially with an expected compound annual growth rate (CAGR) 11.07% from 2024 (237.64 billion USD estimated at end 2023) 2033 (679.03 by 2033). Ever since advent hybridoma technology introduced in 1975, antibody-based therapeutics were realized using murine which further progressed into humanized fully human antibodies, reducing risk immunogenicity. Some benefits over conventional drugs include drastic reduction chances adverse reactions, interactions between drugs, targeting specific proteins. While very efficient, their higher production costs impede process commercialization. However, cost factor been improved developing biosimilar as affordable versions therapeutic antibodies. Along recent advancements innovations antibody engineering have helped will furtherly help design bio-better efficacy than ones. These novel mAb-based set revolutionize existing drug therapies wide diseases, thereby meeting several unmet medical needs. This review provides comprehensive insights current fundamental landscape development applications key factors influencing future projections, advancement, incorporation such promising immunotherapeutic candidates confrontation approach against list rationalistic mentioning any limitations facing this field.
Language: Английский
Citations
4
Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)
Published: Feb. 11, 2025
Fc-fusion peptides, also known as peptibodies, are a promising new category of targeted therapeutics that offer alternatives to monoclonal antibodies (mAbs) for cancer treatment. This study focuses on an peptide consisting the Fc region IgG1 and epidermal growth factor receptor (EGFR)-targeting peptide, GE11, which was identified using phage display method demonstrated high affinity receptor. The fusion (FcIgG-GE11) successfully expressed in Escherichia coli purified ion-exchange chromatography. Flow cytometry confirmed its specific binding EGFR. Like Cetuximab, FcIgG-GE11 peptibody exhibited effective, dose- time-dependent inhibition EGFR-overexpressing cell lines. Additionally, results showed induced death or cycle arrest certain lines, with varying responses depending type. In-Cell ELISA when comparing effects Cetuximab Tyr 1173 phosphorylation were similar. In addition, relative potency compared assessed MTT by Slope Ratio Analysis. These findings suggest can provide efficient tool both targeting treating cells.
Language: Английский
Citations
0